Efficacy and safety of adalimumab in patients with rheumatoid arthritis：a Meta-analysis
10.13699/j.cnki.1001-6821.2016.06.027
- VernacularTitle:阿达木单抗治疗类风湿关节炎有效性和安全性的系统评价
- Author:
Fan WU
1
;
Xiao-Yan SHENG
;
Ling-Yue MA
;
Xia ZHAO
;
Ying ZHOU
;
Yi-Min CUI
Author Information
1. 北京大学第一医院药剂科
- Keywords:
adalimumab;
rheumatoid arthritis;
efficacy;
safety;
Meta-analysis
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(6):563-566
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of adalimumab in patients with rheumatoid arthritis.Methods Electronic databases were searched: PubMed, EMbase, Cochrane library, CNKI, VIP and WanFang Date.The time range of retrieval is from database foundation to June 2015.The included randomized controlled trials were analyzed by the software RevMan 5.3.Results A total of 15 studies, 5209 patients were included.The efficacy of adalimumab with or without concomitant methotrexate ( MTX ) or disease -modifying anti -rheumatic drugs ( DMARDs) was better than placebo or MTX ( or DMARDs).There was no statistically significant difference in the occurrence of serious adverse events between the adalimumab group and the control group( P>0.05).Adalimumab appeared to increase the risk of serious infections compared with placebo or MTX ( or DMARDs).Conclusion Adalimumab is an effective drug for rheumatoid arthritis patients.The risk of adverse events and serious infection should be taken into account when adalimumab is selected.
